Combined pharmacogenetic effect of ADCY9 and ADRB2 gene polymorphisms on the bronchodilator response to inhaled combination therapy

Journal of Clinical Pharmacy and Therapeutics

Volumn 36, Issue 3, 2011, Pages 399-405

  Kim, S H ^a   Ye, Y M ^a   Lee, H Y ^a   Sin, H J ^a   Park, H S ^a  

^a Ajou University School of Medicine   (South Korea)

Author keywords

adenylyl cyclase type 9; asthma; bronchodilator response; gene polymorphism inhaled corticosteroid; long acting 2 agonist

Indexed keywords

ADENYLATE CYCLASE; ADENYLYL CYCLASE TYPE 9; BETA 2 ADRENERGIC RECEPTOR; BUDESONIDE; FORMOTEROL; SALBUTAMOL; UNCLASSIFIED DRUG;

3' UNTRANSLATED REGION; AMINO ACID SUBSTITUTION; ARTICLE; ASTHMA; DISEASE SEVERITY; DRUG EFFECT; DRUG RESPONSE; FORCED EXPIRATORY VOLUME; GENE INTERACTION; GENETIC ASSOCIATION; GENETIC LINKAGE; HAPLOTYPE; HUMAN; MAJOR CLINICAL STUDY; MAXIMAL MID EXPIRATORY FLOW; PHARMACOGENETICS; SINGLE NUCLEOTIDE POLYMORPHISM; TREATMENT OUTCOME;

ADENYLATE CYCLASE; ADMINISTRATION, INHALATION; ADRENERGIC BETA-2 RECEPTOR AGONISTS; ADULT; ASTHMA; BRONCHODILATOR AGENTS; BUDESONIDE; DRUG THERAPY, COMBINATION; ETHANOLAMINES; FEMALE; GENETIC ASSOCIATION STUDIES; GLUCOCORTICOIDS; HUMANS; LINKAGE DISEQUILIBRIUM; MALE; MIDDLE AGED; POLYMORPHISM, GENETIC; RECEPTORS, ADRENERGIC, BETA-2; REPUBLIC OF KOREA; RESPIRATORY SYSTEM; RETROSPECTIVE STUDIES; SEVERITY OF ILLNESS INDEX;

EID: 79955779009     PISSN: 02694727     EISSN: 13652710     Source Type: Journal    
DOI: 10.1111/j.1365-2710.2010.01196.x     Document Type: Article

References (17)

1. O'Byrne PM, Bisgaard H, Godard PP, et al. (2005) Budesonide/formoterol combination therapy as both maintenance and reliever medication in asthma. American Journal of Respiratory and Critical Care Medicine, 171, 129-136. (Pubitemid 40105411)
2. Rabe KF, Pizzichini E, Stallberg B, et al. (2006) Budesonide/formoterol in a single inhaler for maintenance and relief in mild-to-moderate asthma: a randomized, double-blind trial. Chest, 129, 246-256. (Pubitemid 43289841)
3. Mak JC, Nishikawa M, Barnes PJ, (1995) Glucocorticosteroids increase beta 2-adrenergic receptor transcription in human lung. American Journal of Physiology, 268, L41-L46.
4. Adcock IM, Stevens DA, Barnes PJ, (1996) Interactions of glucocorticoids and beta 2-agonists. European Respiratory Journal, 9, 160-168.
5. Aksoy MO, Mardini IA, Yang Y, Bin W, Zhou S, Kelsen SG, (2002) Glucocorticoid effects on the beta-adrenergic receptor-adenylyl cyclase system of human airway epithelium. Journal of Allergy and Clinical Immunology, 109, 491-497. (Pubitemid 34234201)
6. Koopmans JG, Lutter R, Jansen HM, van der Zee JS, (2005) Adding salmeterol to an inhaled corticosteroid reduces allergen-induced serum IL-5 and peripheral blood eosinophils. Journal of Allergy and Clinical Immunology, 116, 1007-1013. (Pubitemid 41571780)
7. Green RH, Brightling CE, McKenna S, et al. (2006) Comparison of asthma treatment given in addition to inhaled corticosteroids on airway inflammation and responsiveness. European Respiratory Journal, 27, 1144-1151. (Pubitemid 44914297)
8. Hall IP, (2006) Pharmacogenetics of asthma. Chest, 130, 1873-1878. (Pubitemid 46033448)
9. Weiss ST, Litonjua AA, Lange C, et al. (2006) Overview of the pharmacogenetics of asthma treatment. Pharmacogenomics Journal, 6, 311-326. (Pubitemid 44480151)
10. Lee DK, Currie GP, Hall IP, Lima JJ, Lipworth BJ, (2004) The arginine-16 beta2-adrenoceptor polymorphism predisposes to bronchoprotective subsensitivity in patients treated with formoterol and salmeterol. British Journal of Clinical Pharmacology, 57, 68-75. (Pubitemid 38067952)
11. Palmer CN, Lipworth BJ, Lee S, Ismail T, Macgregor DF, Mukhopadhyay S, (2006) Arginine-16 beta2 adrenoceptor genotype predisposes to exacerbations in young asthmatics taking regular salmeterol. Thorax, 61, 940-944. (Pubitemid 44787162)
12. Wechsler ME, Lehman E, Lazarus SC, et al. (2006) Beta-adrenergic receptor polymorphisms and response to salmeterol. American Journal of Respiratory and Critical Care Medicine, 173, 519-526.
13. Kim SH, Ye YM, Hur GY, et al. (2009) Effect of beta2-adrenergic receptor polymorphism in asthma control of patients receiving combination treatment. Yonsei Medical Journal, 50, 182-188.
14. Tantisira KG, Small KM, Litonjua AA, Weiss ST, Liggett SB, (2005) Molecular properties and pharmacogenetics of a polymorphism of adenylyl cyclase type 9 in asthma: interaction between beta-agonist and corticosteroid pathways. Human Molecular Genetics, 14, 1671-1677. (Pubitemid 40895519)
15. Small KM, Brown KM, Theiss CT, Seman CA, Weiss ST, Liggett SB, (2003) An Ile to Met polymorphism in the catalytic domain of adenylyl cyclase type 9 confers reduced beta2-adrenergic receptor stimulation. Pharmacogenetics, 13, 535-541. (Pubitemid 37159632)
16. Toyota T, Yamada K, Saito K, Detera-Wadleigh SD, Yoshikawa T, (2002) Association analysis of adenylate cyclase type 9 gene using pedigree disequilibrium test in bipolar disorder. Molecular Psychiatry, 7, 450-452. (Pubitemid 34712895)
17. Ye Y-M, Lee H-Y, Kim S-H, et al. (2009) Pharmacogenetic study of the effects of NK2R G231E G>A and TBX21 H33Q C>G polymorphisms on asthma control with inhaled corticosteroid treatment. Journal of Clinical Pharmacy and Therapeutics, 34, 1-9.